Prevalence and prognosis
After the age of 40, as many as one in five people will develop heart failure (HF) during their lifetime.1 Globally, HF was estimated to affect 64 million people in 2016.2 Despite advances in therapy, morbidity and mortality due to HF remains high.3 In the US, the five-year mortality rate after a diagnosis of HF is approximately 50%.4
The mortality risk of HF is comparable to some of the most common cancers in both men and women.5
HF survival is worse than prostate cancer survival in men5
HF survival is worse than breast cancer survival in women5
patients with heart failure will die within 5 years after diagnosis.4
Burden on society
HF remains a leading healthcare challenge in both high- and low-income countries, despite significant advances in the diagnosis and management of the condition and the extensive body of knowledge available on its pathophysiology.6
Morbidity and mortality related to HF remain high.7 Every patient with HF, regardless of NYHA class, remains at risk of hospitalisation.8 In fact, HF is the leading cause of hospitalisation in patients over the age of 65.9
A significant economic burden
Hospitalisation for HF is associated with tremendous healthcare costs, which will continue to rise.10
- Lloyd-Jones DM, Larson MG, Leip EP, et al. Lifetime risk for developing congestive heart failure: the Framingham Heart Study. Circulation. 2002;106(24):3068-3072.
- GBD 2016 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017;390(10100):1211-1259.
- Westphal JG, Bekfani T, Schulze PC. What's new in heart failure therapy 2018? Interact Cardiovasc Thorac Surg. 2018;27(6):921-930.
- Mozaffarian D, Benjamin EJ, Go AS, et al. Heart Disease and Stroke Statistics-2016 Update: A Report From the American Heart Association. Circulation. 2016;133(4):e38-e360.
- Mamas MA, Sperrin M, Watson MC, et al. Do patients have worse outcomes in heart failure than in cancer? A primary care-based cohort study with 10-year follow-up in Scotland. Eur J Heart Fail. 2017;19(9):1095-1104.
- AstraZeneca and World Heart Federation. Accelerate Change Together Heart Failure Gap Review. June 2020.
- Savarese G and Lund LH. Global public health burden of heart failure. Cardiac Failure Review. 2017;3(1):7-11.
- Ahmed A, Aronow WS, Fleg JL. Higher New York Heart Association classes and increased mortality and hospitalisation in patients with heart failure and preserved left ventricular function. Am Heart J. 2006;151(2):444-450.
- Cowie M, et al. Improving care for patients with acute hear failure: before, during and after hospitalisation. ESC Heart Failure. 2014;1(2):110-145.
- Cowie MR. Presentation at the 2nd World Congress on Acute Heart Failure; 23–26 May 2015; Seville, Spain.
- Lippi G, Sanchis-Gomar F. Global epidemiology and future trends of heart failure. AME Med J. 2020;5:15.